SCHEMBL18197974

SCHEMBL18197974

C=NCc1csc(N=C(N)N)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ATP4A P20648 13/20 0.45
ATP4B P51164 13/20 0.45
HRH2 P25021 3/20 0.45
SLC22A2 O15244 2/20 0.45
CA12 O43570 2/20 0.45
SLC22A3 O75751 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
LMNA P02545 2/20 0.45
TSHR P16473 2/20 0.45
MAOA P21397 2/20 0.45
CA4 P22748 2/20 0.45
CA6 P23280 2/20 0.45
CA5A P35218 2/20 0.45
CA7 P43166 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18197976 0.84 CYP1A2 (0.48) CYP2D6CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL5879530 0.80 CYP1A2 (0.50) CYP2D6CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL16386285 0.79 CYP2D6 (0.44) CYP2D6CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL10776417 0.79 SLC22A2 (0.50) CYP2D6CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL8708729 0.79 CYP1A2 (0.49) CYP2D6CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL18346920 0.77 HRH2 (0.56) CYP2D6CYP1A2CYP2C9CYP2C19SMN1; SMN2
Bromide SCHEMBL8707683 0.77 CYP1A2 (0.48) CYP2D6CYP1A2CYP2C9CYP2C19SMN1; SMN2
Hydrochloric Acid SCHEMBL8934520 0.77 SLC22A2 (0.49) CYP2D6CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL11214613 0.76 HRH2 (0.57) CYP2D6CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL22296554 0.75 HRH2 (0.53) CYP2D6CYP1A2CYP2C9CYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9745274-B2 Compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) 2017-08-29 US disclosed
US-9745274-B2 Compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) 2017-08-29 US disclosed
US-20160318886-A1 Novel Compound, Organic Cation Transporter 3 Detection Agent, And Organic Cation Transporter 3 Activity Inhibitor SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) 2016-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318886-A1 Novel Compound, Organic Cation Transporter 3 Detection Agent, And Organic Cation Transporter 3 Activity Inhibitor SLCO1B3, SLC22A8, SLC10A6 CYP2D6 505/4885CYP1A2 1012/4885CYP2C9 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.